Health Condition 1: F332- Major depressive disorder, recurrent severe without psychotic features Health Condition 2: F334- Major depressive disorder, recurrent, in remission Health Condition 3: F330- Major depressive disorder, recurrent, mild Health Condition 4: F331- Major depressive disorder, recurrent, moderate Health Condition 5: F339- Major depressive disorder, recurrent, unspecified Health Condition 6: F320- Major depressive disorder, singleepisode, mild Health Condition 7: F321- Major dep
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Gowtham S
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients who are prescribed either Venlafaxine or Mirtazapine 2. All genders (male, female and others) 3. Patients above 18 years
Exclusion criteria
Exclusion criteria: 1. Patients not giving written informed consent 2. Pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study the prevalence and pattern of adverse drug reactions (ADRs)Timepoint: 18 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To study severity assessment of ADRsTimepoint: 18 months;To establish the causality assessment of ADRsTimepoint: 18 months;To assess the preventability of ADRsTimepoint: 18 months | — |
Countries
India
Contacts
Public ContactDevesh Gosavi
Mahatma Gandhi Institute of Medical Sciences
Outcome results
None listed